Alexander Drilon

Alexander Drilon, MD is Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center and an internationally recognized leader in kinase fusion oncology. He is the world's foremost expert on RET fusion-positive cancers and has led the pivotal clinical trials that established selpercatinib (LOXO-292, LIBRETTO-001) and pralsetinib (BLU-667, ARROW trial) as highly effective RET-selective inhibitors across multiple tumor histologies including non-small cell lung cancer, thyroid cancer, and other RET fusion-positive solid tumors. Drilon's work on LIBRETTO-001 demonstrated overall response rates exceeding 60% in previously treated RET fusion-positive NSCLC and led to FDA approval of selpercatinib as a tissue-agnostic therapy for RET fusion-positive solid tumors. He has also been instrumental in advancing NTRK fusion detection and entrectinib development and is a leading voice in establishing consensus frameworks for kinase fusion testing in clinical practice.